ELDN Eledon Pharmaceuticals, Inc.
$2.78▲ +0.00%
Healthcare
Other
After hours
$2.82▲ +1.44%
Sep 11, 7:30 PM ET
Volume 638.4K
Avg Volume (10D) 1.08M
Key Metrics & Fundamentals
Market Cap
$225.91M
P/E Ratio
–
Div Yield
–%
52W Range
1.35 - 4.60
% vs 50 MA
-21.23%
% vs 200 MA
-5.90%
RSI-14
26.8
MACD Histogram
-0.0400
Beta (1Y vs SPY)
1.88
Free Cash Flow
-$22.68M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$13.25M
COGS
–
Operating Exp
$22.87M
Operating Income
-$22.87M
EBIT
-$22.87M
Pretax Income
-$31.63M
Net Income
-$31.63M
EPS (Diluted)
-0.27
Price & Volume History
Loading chart…
Recent News
Top Premarket Gainers
MT Newswires · Sep 11, 2026 11:14 AM
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
GlobeNewswire · Sep 9, 2026 11:00 AM
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart
MT Newswires · Sep 3, 2026 11:49 AM
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
GlobeNewswire · Sep 3, 2026 11:00 AM
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · Aug 13, 2026 8:05 PM
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
CNW Group · Jul 21, 2026 1:00 PM
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
GlobeNewswire · Jul 8, 2026 1:15 PM
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
GlobeNewswire · Jul 1, 2026 1:30 PM
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial
MT Newswires · Jun 25, 2026 12:05 PM
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Business Wire · Jun 25, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ELDN's money flow as a full page
Social Sentiment
Avg +0.77 · 3 posts
NewsDiscussionTradePotential Type 1 Diabetes Cure
r/wallstreetbets · Jun 8, 2026
The author expresses strong belief in the stock's potential due to the positive study results and market capitalization.
very_positive
+0.80
NewsDDELDN showing incredible data
r/investing · Mar 23, 2026
The post expresses excitement about the clinical trial results and encourages investment, indicating a bullish sentiment.
positive
+0.70
NewsDDELDN showing incredible data
r/wallstreetbets · Mar 23, 2026
The positive results regarding the therapy and the large number of patients off insulin suggest strong potential for the company.
positive
+0.80
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.